Adimmune (TPE:4142) Issuance of Debt: NT$1,742 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4142 Adimmune Corp TPE:4142
60 GF Score
Price NT$17.40
GF Value NT$20.07
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Adimmune Issuance of Debt?

Adimmune TPE:4142 -0.85% 60 Issuance of Debt is NT$1,742 Mil as of Mar. 2026. GuruFocus rates TPE:4142 with a GF Score™ of 60/100 and a GF Value™ of NT$20.07 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Adimmune's Issuance of Debt for the three months ended in Mar. 2026 was NT$0 Mil.

Adimmune's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was NT$1,742 Mil.

Adimmune Issuance of Debt Related Terms

Adimmune Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Adimmune's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Issuance of Debt Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 918.00 1,064.90 66.11 1,958.56

Adimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 216.82 206.85 342.39 1,192.50 0.00
TPE:4142
60GF Score
Adimmune Corp TPE:4142
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,742 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of NT$1,742 Mil mean?
Adimmune (TPE:4142) has a Issuance of Debt of NT$1,742 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Adimmune and its competitors.
Is Adimmune's Issuance of Debt too high?
Adimmune's current Issuance of Debt is NT$1,742 Mil. Overall, Adimmune has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Issuance of Debt compare to VRTX and REGN?
Adimmune's Issuance of Debt of NT$1,742 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Adimmune and its competitors. Adimmune's current Issuance of Debt is NT$1,742 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.07, compared to a current price of NT$17.40 — trading 13.3% below its estimated fair value. The current Issuance of Debt is NT$1,742 Mil. Adimmune's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Issuance of Debt is NT$1,742 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.40 is trading 13.3% below its estimated GF Value™ of NT$20.07. GuruFocus considers Adimmune to be Modestly Undervalued.

Key valuation signals for TPE:4142:

  • Issuance of Debt: NT$1,742 Mil
  • GF Value™: NT$20.07 vs. price of NT$17.40 (13.3% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
60GF Score

Get the complete analysis for TPE:4142

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.40
Price
NT$20.07
GF Value